Since the introduction of anatomical and functional imaging with multiparametric magnetic resonance imaging and choline or prostate-specific membrane antigen positron emission tomography-computed tomography, we are able to diagnose a previously unknown disease, the oligometastatic prostate cancer after local therapy. Reports on surgical and radiation treatment for low-volume metastatic recurrence have shown promising results, with definitive cure in few but a relevant delay of androgen-deprivation therapy with both treatment methods. Obviously, these results need to be validated with prospective randomised data.
Keywords: (SB)RT, (stereotactic body) radiotherapy; ADT, androgen-deprivation therapy; BRFS, biochemical recurrence-free survival; CPFS, clinical progression-free survival; CSS, cancer-specific survival; LND, lymph node dissection; Lymph node dissection; Oligometastatic prostate cancer; PET, positron emission tomography; Stereotactic body radiotherapy.